Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-06-28

Clinical Trial Update: 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on 68Ga-PSMA PET imaging for biochemical recurrence of prostate cancer, with Phase 2/3 results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • 68Ga-PSMA-11 (Gallium-68 labeled PSMA-11 radiopharmaceutical)

Snippet

Sponsor: Michael Graham PhD, MD | Conditions: Prostate Cancer, Prostatic Neoplasm | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2024-06-28